Company Adocia

Equities

ADOC

FR0011184241

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Ratings for Adocia

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Euronext Paris Other stock markets 06:44:24 2024-04-25 am EDT			5-day change	1st Jan Change
8.17 ^EUR	-6.63%		-2.85%	-29.20%

Apr. 24	Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 22	Adocia: announces fund-raising	CF

Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes.

At the end of 2022, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).

Number of employees: 97

EUR in Million	2021	Weight	2022	Weight	Delta
Regenerative Medicine 100.0 %	1	100.0 %	11	100.0 %	+692.73%

EUR in Million	2021	Weight	2022	Weight	Delta
France 100.0 %	1	100.0 %	11	100.0 %	+692.73%

Managers	Title	Age	Since
Olivier Soula FOU	Founder	53	05-12-15
Gérard Soula FOU	Founder	78	05-12-15
Valérie Danaguezian DFI	Director of Finance/CFO	-	05-12-31
Géraldine Favre-Soula HRO	Human Resources Officer	-	-

Members of the board	Title	Age	Since
Gérard Soula FOU	Founder	78	05-12-15
Katherine Bowdish BRD	Director/Board Member	67	21-05-20
Ekaterina Smirnyagina BRD	Director/Board Member	58	13-06-17
Stéphane Boissel BRD	Director/Board Member	56	21-05-20
Olivier Soula FOU	Founder	53	05-12-15
Mads Dall BRD	Director/Board Member	-	-
Claudia Mitchell BRD	Director/Board Member	-	21-05-20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	9,748,740	9,268,810 ( 95.08 %)	28,970 ( 0.2972 %)	95.08 %

Name	Equities	%	Valuation
BPIFrance Investissement SAS 7.682 %	1,082,427	7.682 %	10 M €
Gérard Soula 7.143 %	1,006,455	7.143 %	10 M €
Société Hospitalière d'Assurances Mutuelles SAM 2.271 %	320,000	2.271 %	3 M €
Olivier Soula 2.200 %	310,040	2.200 %	3 M €
Rémi Soula 1.978 %	278,690	1.978 %	3 M €
Groupe des Assurances du Crédit Mutuel SA 0.8939 %	125,944	0.8939 %	1 M €
NOVACAP Asset Management SA 0.3015 %	42,478	0.3015 %	401 876 €
Oreo Finance SASU 0.2879 %	40,561	0.2879 %	383 740 €
ADOCIA 0.2826 %	39,816	0.2826 %	376 691 €
OP Asset Management Ltd. 0.2634 %	37,113	0.2634 %	351 119 €

Name	Equities	%	Valuation
ADOCIA 0.28%	39,816	0.28%	376,691 $

Adocia SA

115 avenue Lacassagne

69003, Lyon

+33 4 72 61 06 10

http://www.adocia.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

8.75 EUR

Average target price

9.7 EUR

Spread / Average Target

+10.86%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ADOCIA	-29.20%	134M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.46%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-9.03%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs